Phase II trial of MEDI0457 and durvalumab for patients with recurrent/metastatic HPV-associated cancers.
Van K. Morris(The University of Texas MD Anderson Cancer Center), Michaela Onstad(The University of Texas MD Anderson Cancer Center), Benny Johnson(The University of Texas MD Anderson Cancer Center), Ying Yuan(The University of Texas MD Anderson Cancer Center), Aaron Shafer(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Ming Guo(The University of Texas MD Anderson Cancer Center), Solly George(The University of Texas MD Anderson Cancer Center), Jennifer Wang(The University of Texas MD Anderson Cancer Center), David Vining(The University of Texas MD Anderson Cancer Center), Ryan Huey(The University of Texas MD Anderson Cancer Center), Lianchun Xiao(The University of Texas MD Anderson Cancer Center), Curtis A. Pettaway(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Shi‐Ming Tu(University of Arkansas for Medical Sciences)
Cited by 8
Related Papers
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
|Journal of Clinical Oncology|2022|580
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
|Nature Medicine|2023|508